Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amlodipine besylate + arginine is a combination product consisting of **amlodipine besylate**, a long-acting dihydropyridine calcium channel blocker used as an antihypertensive and antianginal agent, together with **arginine**, an amino acid commonly marketed as L-arginine that serves as a nitric oxide precursor and may promote vasodilation. The exact identified product corresponding to this name appears to be a kit presentation rather than a single novel molecular entity, and there is limited evidence that this exact combination is a broadly established branded pharmaceutical with a distinct development program. Mechanistically, amlodipine inhibits L-type calcium influx in vascular smooth muscle to reduce peripheral vascular resistance, while arginine may increase nitric oxide production and thereby augment vasodilatory effects. The combination would most plausibly be relevant to blood pressure management or cardiovascular support, but the exact regulatory and commercial status of the specific named combination is not well characterized.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amlodipine besylate + arginine.